Fulvestrant for the treatment of advanced breast cancer

Blackburn, Sophie A.; Parks, Ruth M.; Cheung, Kwok-Leung

Abstract

Introduction: The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degrader (SERD), has been demonstrated in hormone receptor positive patients previously untreated or treated with hormonal therapy.
Areas covered: This article discusses the journey of fulvestrant licensing, its efficacy in combination with other endocrine therapies and the future role it may have within breast cancer treatment.
Expert commentary: Within phase III trials, fulvestrant has demonstrated equivalent or improved clinical efficacy when compared with established endocrine agents. In the recent decade, fulvestrant has achieved licensing as a second line agent in non-operative advanced breast cancer at initially 250mg, increasing to 500mg. Presently, fulvestrant is licensed globally as first line endocrine management for advanced breast cancer in post-menopausal women. Early combination trials of fulvestrant and cyclin dependent kinase 4/6 inhibitors have demonstrated good clinical efficacy with improved progression free survival when compared to fulvestrant alone.

Citation

Blackburn, S. A., Parks, R. M., & Cheung, K.-L. (2018). Fulvestrant for the treatment of advanced breast cancer. Expert Review of Anticancer Therapy, 18(7), 619-628. https://doi.org/10.1080/14737140.2018.1473038

• Journal Article Type: Article
• Acceptance Date: May 2, 2018
• Online Publication Date: May 11, 2018
• Publication Date: May 15, 2018
• Deposit Date: Jun 28, 2018
• Publicly Available Date: May 12, 2019
• Journal: Expert Review of Anticancer Therapy
• Print ISSN: 1473-7140
• Electronic ISSN: 1744-8328
• Publisher: Taylor and Francis
• Peer Reviewed: Peer Reviewed
• Volume: 18
• Issue: 7
• Pages: 619-628
• DOI: https://doi.org/10.1080/14737140.2018.1473038
• Keywords: Fulvestrant, advanced breast cancer, endocrine therapy, pure anti-oestrogen
• Public URL: https://nottingham-repository.worktribe.com/output/932673
• Publisher URL: https://www.tandfonline.com/doi/abs/10.1080/14737140.2018.1473038
• Additional Information: This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Anticancer Therapy on 11 May 2018, available online: http://www.tandfonline.com/10.1080/14737140.2018.1473038
• Contract Date: Jun 28, 2018